Close

Actavis' (ACT) Move to Acquire Durata (DRTX) is Strategically Sound; Signals Appetite for More M&A - Moody's

October 7, 2014 11:37 AM EDT

Moody's Investors Service commented that Actavis plc's (NYSE: ACT) acquisition of Durata Therapeutics Inc. (Nasdaq: DRTX) is strategically sound, but signals continued appetite for acquisitions at a a time when the company is still integrating its $28 billion acquisition of Forest Laboratories. There is no change to Actavis' Baa3 senior unsecured rating or the stable outlook.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Credit Ratings

Related Entities

Moody's Investors Service, Definitive Agreement